علاج سرطان المعدة في إسرائيل — احصل على 3 عيادات مختارة خصيصاً لك

Stomach cancer treatment in Israel involves multidisciplinary protocols combining D2 lymphadenectomy, advanced chemotherapy, and targeted immunotherapy. JCI-accredited centers like Sourasky and Sheba specialize in Da Vinci robotic resections. This technology improves surgical precision and accelerates recovery times for gastric cancer patients.

• Surgical resection: Performs partial or total gastrectomy with D2 lymph node dissection protocols.
• Robotic systems: Utilizes Da Vinci technology for minimally invasive tumor removal and reconstruction.
• Advanced chemotherapy: Employs perioperative FLOT protocols or HIPEC heated chemotherapy for peritoneal spread.
• Targeted therapy: Applies HER2-specific biological agents like Herceptin or Keytruda immunotherapy for advanced stages.

Bookimed Expert Insight: Israeli oncology centers demonstrate high efficiency by integrating rapid molecular diagnostics with surgical planning. Data shows Sourasky Medical Center maintains a 90% oncology success rate while treating over 400,000 patients annually. For patients seeking robotic surgery, Dr. Pelles Sharon and Professor Ido Nachmany are noted specialists who utilize these minimally invasive techniques to reduce hospital stays.

Patient Consensus: Patients note it's important to arrange private care to avoid long public waitlists and emphasize the value of detailed treatment plans provided by specialists. Many feel more confident after receiving clear explanations about robotic options and supportive care for post-surgery recovery.

Top hospitals for stomach cancer in Israel include Sheba Medical Center, Sourasky Medical Center (Ichilov), and Hadassah Medical Center. These JCI-accredited facilities offer advanced gastric resection, HIPEC, and Da Vinci robotic surgery. They maintain high oncology success rates through multidisciplinary tumor boards and precision medicine protocols.

• Sheba Medical Center: Largest regional facility treating 2,000,000 patients annually with specialized HIPEC programs.
• Sourasky Medical Center: Reports 90% oncology success rate using robotic-assisted gastrectomy and targeted therapies.
• Hadassah Medical Center: Follows university-hospital protocols for complex cases with over 40,000 annual surgeries.
• Assuta Medical Center: Private network providing rapid access to laparoscopic and robotic gastrointestinal oncology procedures.

Bookimed Expert Insight: Patient volume data often reveals hidden expertise in specific surgical techniques. While Sourasky handles over 400,000 patients yearly, specialists like Dr. Joseph Klauzner bring over 45 years of experience to complex gastrointestinal surgeries. Choosing a high-volume center with senior surgeons who perform 1,000+ procedures ensures access to refined recovery protocols and lower complication risks.

Patient Consensus: Patients note the value of getting a treatment plan quickly through remote consultations with specialists like Dr. Pelles Sharon or Professor Ayala Hubert. Personal coordination is often the deciding factor for those seeking fast access to advanced robotic surgery or clinical trials.

Stomach cancer surgery in Israel typically requires a 5 to 14 day hospital stay. Minimally invasive robotic or laparoscopic procedures often reduce this to 3 days. Full physical recovery generally takes 8 weeks. Long-term dietary adjustments commonly continue for up to 12 months.

• Hospital stay: Partial gastrectomy requires 3–7 days while total removal takes 7–14 days.
• Minimally invasive: Robotic-assisted surgery with Da Vinci systems reduces stays to 3–5 days.
• Initial recovery: Patients transition from liquid to soft foods during the first 4 weeks.
• Work return: Most patients resume non-strenuous professional activities within 6 weeks post-operation.

Bookimed Expert Insight: Israeli oncology centers like Sourasky (Ichilov) maintain a 90% success rate by prioritizing rapid mobilization. Data shows that even for complex gastric resections, surgeons like Dr. Joseph Klauzner leverage over 45 years of experience to minimize inpatient time. Many high-volume centers in Tel Aviv combine surgery with immediate post-operative monitoring efficiently, often allowing international patients to safely fly home within 15 days of the procedure.

Patient Consensus: Patients often note that while initial discharges happen quickly, the real challenge is managing small, frequent meals at home. Many express gratitude for detailed treatment plans that clarify the transition from hospital care to independent recovery.

Targeted and biological therapies are routinely used for gastric cancer in Israel as part of the National Health Basket. Treatment selection depends on molecular profiling to match specific drugs to the tumor. Common options include Trastuzumab for HER2-positive cases and immunotherapy like Pembrolizumab for specific genetic markers.

• Biomarker testing: Doctors use genomic profiling to identify specific mutations or protein levels.
• HER2 status: Approximately 20% of patients qualify for Trastuzumab-based therapies if HER2-positive.
• Immunotherapy indicators: High PD-L1 levels or MSI-H status guide the use of biological agents.
• Drug variety: Advanced options include Ramucirumab for second-line treatment and Panitumumab for EGFR inhibition.

Bookimed Expert Insight: Israeli oncology centers like Sourasky Medical Center prioritize academic research integration for complex cases. Dr. Pelles Sharon at Sourasky specifically focuses on clinical trials for digestive system cancers. This means patients may access experimental biological therapies before they become global standards. Our data shows a 90% oncology success rate at this JCI-accredited facility in Tel Aviv.

Patient Consensus: Patients emphasize the need to explicitly request HER2 and MSI/MMR testing during the initial consultation. Many note that while major centers in Tel Aviv offer advanced options, availability can vary in smaller regional hospitals.